Suppr超能文献

美国非医疗机构抗惊厥药物用药错误

Non-health care facility anticonvulsant medication errors in the United States.

作者信息

DeDonato Emily A, Spiller Henry A, Casavant Marcel J, Chounthirath Thitphalak, Hodges Nichole L, Smith Gary A

机构信息

1 Center for Injury Research and Policy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.

2 The Ohio State University College of Medicine, Columbus, OH, USA.

出版信息

Hum Exp Toxicol. 2018 Jun;37(6):561-570. doi: 10.1177/0960327117721962. Epub 2017 Jul 25.

Abstract

INTRODUCTION

This study provides an epidemiological description of non-health care facility medication errors involving anticonvulsant drugs.

METHODS

A retrospective analysis of National Poison Data System data was conducted on non-health care facility medication errors involving anticonvulsant drugs reported to US Poison Control Centers from 2000 through 2012.

RESULTS

During the study period, 108,446 non-health care facility medication errors involving anticonvulsant pharmaceuticals were reported to US Poison Control Centers, averaging 8342 exposures annually. The annual frequency and rate of errors increased significantly over the study period, by 96.6 and 76.7%, respectively. The rate of exposures resulting in health care facility use increased by 83.3% and the rate of exposures resulting in serious medical outcomes increased by 62.3%. In 2012, newer anticonvulsants, including felbamate, gabapentin, lamotrigine, levetiracetam, other anticonvulsants (excluding barbiturates), other types of gamma aminobutyric acid, oxcarbazepine, topiramate, and zonisamide, accounted for 67.1% of all exposures.

CONCLUSIONS

The rate of non-health care facility anticonvulsant medication errors reported to Poison Control Centers increased during 2000-2012, resulting in more frequent health care facility use and serious medical outcomes. Newer anticonvulsants, although often considered safer and more easily tolerated, were responsible for much of this trend and should still be administered with caution.

摘要

引言

本研究提供了涉及抗惊厥药物的非医疗机构用药错误的流行病学描述。

方法

对2000年至2012年向美国毒物控制中心报告的涉及抗惊厥药物的非医疗机构用药错误进行了国家毒物数据系统数据的回顾性分析。

结果

在研究期间,向美国毒物控制中心报告了108446起涉及抗惊厥药物的非医疗机构用药错误,每年平均有8342次暴露。在研究期间,错误的年发生率和发生率分别显著增加了96.6%和76.7%。导致使用医疗机构的暴露率增加了83.3%,导致严重医疗后果的暴露率增加了62.3%。2012年,新型抗惊厥药物,包括非氨酯、加巴喷丁、拉莫三嗪、左乙拉西坦、其他抗惊厥药物(不包括巴比妥类药物)、其他类型的γ-氨基丁酸、奥卡西平、托吡酯和唑尼沙胺,占所有暴露的67.1%。

结论

2000年至2012年期间,向毒物控制中心报告的非医疗机构抗惊厥药物用药错误率有所增加,导致使用医疗机构的频率更高,医疗后果更严重。新型抗惊厥药物虽然通常被认为更安全、耐受性更好,但在很大程度上导致了这一趋势,仍应谨慎使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验